Treatment: Steroids

  • Hee Seung Lee
  • Seungmin BangEmail author


Like autoimmune pancreatitis (AIP), IgG4-related sclerosing cholangitis (IgG4-SC) responds well to steroids, and serum IgG4 falls simultaneously during treatment. Steroid treatment is divided as induction phase, tapering phase, and maintenance phase. Although the starting dose of steroids is not established yet worldwide, it would be reasonable to use the same drug regimen as for AIP, starting at 0.6 mg/kg/day (or 30–60 mg/day) and titrating down the dose as the laboratory results including serum IgG4 improve. A response is expected within 2–4 weeks of steroid treatment. On the other hand, opinion for maintenance treatment is different between Asian and Western countries. The dose is usually tapered to a maintenance dose (2.5–5 mg/day) over a period of 2–3 months, based on changes in clinical manifestations, biochemical blood tests, and imaging findings. Cessation of steroid therapy should be based on the disease activity in each case. The initial response rate to steroid of IgG4-SC was up to 90–97%.


IgG4-related sclerosing cholangitis Autoimmune pancreatitis IgG4-related disease Treatment Steroid 


  1. 1.
    Zen Y, Kawakami H, Kim JH. IgG4-related sclerosing cholangitis: all we need to know. J Gastroenterol. 2016;51(4):295–312.CrossRefPubMedGoogle Scholar
  2. 2.
    Smit WL, Culver EL, Chapman RW. New thoughts on immunoglobulin G4-related sclerosing cholangitis. Clin Liver Dis. 2016;20(1):47–65.CrossRefPubMedGoogle Scholar
  3. 3.
    Hubers LM, Maillette de Buy Wenniger LJ, Doorenspleet ME, Klarenbeek PL, Verheij J, Rauws EA, et al. IgG4-associated cholangitis: a comprehensive review. Clin Rev Allergy Immunol. 2015;48(2–3):198–206.CrossRefPubMedGoogle Scholar
  4. 4.
    Hart PA, Zen Y, Chari ST. Recent advances in autoimmune pancreatitis. Gastroenterology. 2015;149(1):39–51.CrossRefPubMedGoogle Scholar
  5. 5.
    Okazaki K, Uchida K, Koyabu M, Miyoshi H, Ikeura T, Takaoka M. IgG4 cholangiopathy: current concept, diagnosis, and pathogenesis. J Hepatol. 2014;61(3):690–5.CrossRefPubMedGoogle Scholar
  6. 6.
    Kamisawa T, Shimosegawa T, Okazaki K, Nishino T, Watanabe H, Kanno A, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009;58(11):1504–7.CrossRefPubMedGoogle Scholar
  7. 7.
    Moon SH, Kim MH, Park DH, Hwang CY, Park SJ, Lee SS, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008;57(12):1704–12.CrossRefPubMedGoogle Scholar
  8. 8.
    Kamisawa T, Okazaki K, Kawa S, Ito T, Inui K, Irie H, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014;49(6):961–70.CrossRefPubMedGoogle Scholar
  9. 9.
    Hirano K, Tada M, Isayama H, Yagioka H, Sasaki T, Kogure H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007;56(12):1719–24.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Pearson RK, Longnecker DS, Chari ST, Smyrk TC, Okazaki K, Frulloni L, et al. Controversies in clinical pancreatology: autoimmune pancreatitis: does it exist? Pancreas. 2003;27(1):1–13.CrossRefPubMedGoogle Scholar
  11. 11.
    Ghazale A, Chari ST, Zhang L, Smyrk TC, Takahashi N, Levy MJ, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134(3):706–15.CrossRefPubMedGoogle Scholar
  12. 12.
    Finkelberg DL, Sahani D, Deshpande V, Brugge WR. Autoimmune pancreatitis. N Engl J Med. 2006;355(25):2670–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol. 2014;109(10):1675–83.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Tomiyama T, Uchida K, Matsushita M, Ikeura T, Fukui T, Takaoka M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2011;46(5):696–704.CrossRefPubMedGoogle Scholar
  15. 15.
    Park DH, Kim MH, Oh HB, Kwon OJ, Choi YJ, Lee SS, et al. Substitution of aspartic acid at position 57 of the DQ beta 1 affects relapse of autoimmune pancreatitis. Gastroenterology. 2008;134(2):440–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Hart PA, Kamisawa T, Brugge WR, Chung JB, Culver EL, Czako L, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013;62(12):1771–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Tanaka A, Tazuma S, Okazaki K, Nakazawa T, Inui K, Chiba T, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017;15(6):920–6 e3.CrossRefPubMedGoogle Scholar
  18. 18.
    Raina A, Yadav D, Krasinskas AM, McGrath KM, Khalid A, Sanders M, et al. Evaluation and management of autoimmune pancreatitis: experience at a large US center. Am J Gastroenterol. 2009;104(9):2295–306.CrossRefPubMedGoogle Scholar
  19. 19.
    Sandanayake NS, Church NI, Chapman MH, Johnson GJ, Dhar DK, Amin Z, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009;7(10):1089–96.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2019

Authors and Affiliations

  1. 1.Division of Gastroenterology, Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations